Document is current

Article History

Received: 28 October 2021

Accepted: 15 September 2022

First Online: 23 September 2022

Declarations

:

: The protocol of this study was approved by the Institutional Review Board of each participating center. All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: Written informed consent was obtained from all individual participants included in the study.

: YN reports speakers’ bureau fees from Pfizer outside the submitted work. T. Tachibana reports speakers’ bureau fees from Otsuka Pharmaceutical, Novartis Pharma, Pfizer, BMS, Daiichi Sankyo, and Amgen outside the submitted work. ES reports speakers’ bureau fees and/or grants from BMS, Pfizer, Novartis Pharma, and Celgene and grants from Kyowa Kirin, Chugai Pharmaceutical, and Ono Pharmaceutical outside the submitted work. SM reports speakers’ bureau fees and/or grants from Boehringer Ingelheim, AstraZeneca, BMS, Chugai Pharmaceutical, Eli Lilly and Company, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical outside the submitted work. SO reports speakers’ bureau fees and/or grants from Astellas Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Sanofi, Daiichi Sankyo, Takeda Pharmaceutical, Chugai Pharmaceutical, Novartis Pharma, Mochida Pharmaceutical, JCR Pharma, Pfizer Nihon Shinyaku, and BMS and grants from Asahi Kasei Pharma, Shionogi, Dainihon Sumitomo, and Teijin Pharma outside the submitted work. YK reports speakers’ bureau fees and/or grants from Astellas Pharmaceuticals, Dainihon Sumitomo, Chugai Pharmaceutical, Eisai, MSD, Pfizer, Novartis Pharma, Otsuka Pharmaceutical, and Janssen Pharmaceutical and grants from Celgene, Kyowa Kirin, Ono Pharmaceutical, Takeda Pharmaceutical, and Shionogi outside the submitted work. The other authors declare no competing financial interests.